Regulatory MSD takes on Pfizer’s Prevnar with new Capvaxive approval PharmaphorumMSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 21, 2026) Pharmaphorum MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New biotech cAMPfield emerges with $180M to reshape IBD treatmentNext: Next Post Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
